3 days popular7 days popular1 month popular3 months popular

Celgene determined to continue fight for patient access to its metastatic pancreatic cancer treatment despite negative NICE decision

NICE (the National Institute for Health and Care Excellence) issued its Final Appraisal Determination (FAD) on Abraxane® (paclitaxel formulated as albumin bound nanoparticles; nab-paclitaxel) in combination with gemcitabine, and has not recommended it for use by for the treatment of metastatic adenocarcinoma of the pancreas.[i]

In addition, an NHS England review of 42 cancer treatments currently available through the Cancer Drugs Fund () could result in Abraxane® being ‘de-listed’,[ii] despite being added to the list earlier this year and the All Wales Medicines Strategy Group (AWMSG) recommending it for use.[iii] Abraxane® in combination with gemcitabine was added to the CDF in March 2014[iv], following support from 70 leading pancreatic cancer specialists to include it on the list. So far over 260 metastatic pancreatic cancer patients have been able to access Abraxane® through the CDF.[v],[vi]

Source

[i] NICE Final Appraisal Determination. December 2014

[ii] NHS England. NHS England list of drugs to be assessed at the next meeting of the national CDF panel – December 2014. http://www.england.nhs.uk/ourwork/pe/cdf/drugs-assess/. Accessed December 2014

[iii] All-Wales Medicines Strategy Group. Appraisal Information for paclitaxel albumin-bound nanoparticles (Abraxane®). Available at http://www.awmsg.org/awmsgonline/app/appraisalinfo/1999. Accessed December 2014

[iv] NHS England. Cancer Drug Fund decision summaries. http://www.england.nhs.uk/ourwork/pe/cdf/cdf-drug-sum/#mar. Accessed November 2014

[v] NHS England Quarterly figures – including notifications and Individual Cancer Drug Fund Requests (ICDFRs) March 2013-April 2014 (taken from http://www.england.nhs.uk/ourwork/pe/cdf/ Accessed December 2014)

[vi] NHS England Quarterly figures – including notifications and Individual Cancer Drug Fund Requests (ICDFRs) April 2014-September 2014 (taken from http://www.england.nhs.uk/ourwork/pe/cdf/ Accessed December 2014)

Source: Celgene